展望未来：在风湿性疾病中针对治疗的重组蛋白和小分子药物。
A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases.
机构信息
Abteilung für Molekulare Immunologie, Nikolaus-Fiebiger-Zentrum, Erlangen, Germany.
出版信息
Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S168-70.
PMID:19822067
Abstract
Whether the differences in the clinical picture and in the pathogenesis between rheumatoid arthritis (RA) and ankylosing spondylitis (AS) will lead to different therapeutic approaches is unclear at present. Since anti-TNF-alpha agents and other biologics are not efficacious in all patients new developments are clearly needed.
摘要
目前尚不清楚类风湿关节炎 (RA) 和强直性脊柱炎 (AS) 之间在临床表现和发病机制上的差异是否会导致不同的治疗方法。由于抗 TNF-α 制剂和其他生物制剂并非对所有患者都有效，因此显然需要新的发展。
Zotero 插件